EnanDIM - a novel family of L-nucleotide-protected TLR9 agonists for cancer immunotherapy.

J Immunother Cancer · 2019 · PMC6323716 · PMID 30621769

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

Long-lasting immune memory through EnanDIM® in EMT-6 and A20 murine tumor models Treatment of mice with EnanDIM-C in the syngeneic A20 lymphoma model showed substantial tumor growth inhibition (TGI) of 78% and a highly significant increase of survival (Fig. 6 a).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.